DOT Desk :  Bangavax, a single-dose Covid-19 vaccine developed by local pharmaceutical company Globe Biotech Ltd, has been approved by Bangladesh Medical Research Council (BMRC) for human trials, reports Daily Sun.
 “The BMRC has given us ethical permission to conduct Bangavax trials on humans and now we’ll submit a protocol to Directorate General for Drug Administration for clinical trial,” said Dr Md Mohiuddin, Senior Manager (quality and regulation) of Globe Biotech Ltd.
 BMRC director Prof Md Ruhul Amin said, “Globe Biotech is now able to conduct Phase-I trial, fulfilling the conditions set by the BMRC. The company will get clearance for widespread use of the vaccine if Phase-2 and Phase-3 trials are found effective and safe enough.”
 Earlier, the vaccine developers responded to all the queries and observations of the BMRC to get nod for Bangavax trials on humans. On July 2 in 2020, Globe Biotech declared that it developed a Covid-19 vaccine. The results of the trials on animals were published on the Bio-Archive on September 29. The pharmaceutical company in September of the same year also announced its plan to launch Bangavax trials on humans after completing Phase-II animal trials.
On October 5 last year, Globe Biotech claimed that it found ‘very promising results’ in Bangavax trials on rabbits and mice. Researchers initially named the vaccine ‘Bancovid’ but later renamed it ‘Bangavax’.